secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2026-06-09T21:32:31+00:00
Accession:  0001193125-26-264085
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics doubles authorized common shares to 200M, annual meeting votes pass
--------------------------------------------------------------------------------

- Stockholders approved amendment increasing authorized common shares from 100M to 200M; effective June 9, 2026.
- Elected Class III directors Richard Fair and Lori Kunkel with 99.7% and 64.7% of votes cast, respectively.
- Ratified Deloitte & Touche as independent auditor for FY2026 with overwhelming support (56.1M for).
- Advisory say-on-pay approved (47.6M for, 89.5% of votes cast); advisory vote on frequency set to every one year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312526264085/0001193125-26-264085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312526264085/d152745d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-264085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer